A Phase 2/3 interventional study of tadalafil and Sildenafil in IVF, sponsored by Beni-Suef University. Not yet recruiting at 1 site in Egypt. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2023-08-03.
Sponsored by Beni-Suef University · Phase 2/3, Interventional, and Treatment
The aim of this study is to investigate the Effect of different vasodilators as Tadalafil, Sildenafil and pentoxyfylline in In vitro Fertilization. In addition, the thickness of endometrium and pregnancies rates of these women will also be examined. All adverse effects of all drugs will be estimated
A prospective randomized clinical study will be conducted in the IVF clinic of the gynecology department of Beni Suef University Hospital, Beni-Suef, Egypt. The study will These patients will be randomized into four groups.
The participants will take drugs starting from the end of menstruation cycle till endometrium reach optimal and then will start progesterone 800 mg daily.
Beni-Suef University is the lead sponsor of 333 studies on the registry; 116 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
tadalafil 10 mg one tablet daily
Drug: tadalafil
pentoxyfilline 400 mg two tabs daily
Drug: pentoxifylline
sildenafil 20 mg two tablets
Drug: Sildenafil
no intervention is given
tadalafil 10 mg one tablet daily
Also known as: cialong
sildenafil 20 mg two tablets daily
Also known as: Respatio
pentoxifylline 400 mg two tabs daily
Also known as: trental
endometrial thickness
measured by transvaginal ultrasound
Time frame: within 16 day of menstruation
pregnancy rate
number of cases positive serum pregnancy test
Time frame: 1 month
Plan to share: Undecided
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beni-Suef University